Clincosm LogoSign in Get a demo

To Check Safety of Ayurvedic Oral Cannabis in Breast and Head and Neck Cancer

Sponsor
Tata Memorial Hospital (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05969314
Collaborator
(none)
12
Enrollment
2
Locations
1
Arm
18.8
Anticipated Duration (Months)
6
Patients Per Site
0.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Phase 1 study to assess the pharmacokinetic availability and safety and tolerability profile of one such ayurvedic preparation which contains 5 mg THC:CBD 1:1 preparation. Other than the PK profile, we will also be studying its effect on gene expression profiling of the breast and head neck oral cavity squamous cell carcinoma tissue.

Condition or Disease Intervention/Treatment Phase
  • Drug: Cannabis capsules
 Phase 1

Detailed Description

The ancient Ayurvedic medicine obtained from Cannabis sativa plant has recently been re-explored for its anti-inflammatory and anti-cancer potential. Various laboratory and preclinical studies have proven its anti-cancer activity and its effect on all the hallmarks of cancer. Anecdotal clinical evidence has shown regression of tumours with ingestion of such medicinal cannabis. A randomized controlled trial in Glioblastoma Multiforme, a kind of brain tumour, shows improvement in disease free survival when temozolamide was combined with Cannabis spray called Sativex.

However, because of lack of systematic, large volume studies, the evidence is slow to emerge. We have previously seen changes related to NF-kb (inflammation) and AP1 (acute hypoxia/stress) pathway genes within the tumour tissue as assessed by transcriptomic analysis (Yet unpublished data). There is laboratory evidence to suggest that the changes induced in the AP1 pathway during surgery can be ameliorated by cannabis treatment. We intend to explore this anticancer potential of C sativa herbal preparation in the pre-operative setting in breast and head and neck cancer patients. Hence, we are proposing a phase 1 study to assess the pharmacokinetic availability and safety and tolerability profile of one such ayurvedic preparation which contains 5 mg THC:CBD 1:1 preparation. Other than the PK profile, we will also be studying its effect on gene expression profiling of the breast and head neck oral cavity squamous cell carcinoma tissue.

Study Design

Study Type:
Interventional
Actual Enrollment :
12 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
To determine the maximum tolerated dose (MTD). First 3 patients will receive the study preparation once a day at 9 am (+/- 60 min) (i.e 5 mg of CBD and 5 mg of THC in a 400 mg capsule). Subsequent cohorts will be administered doses of 10 (10 mg of THC and CBD each), 20 (20+20) and 30 (30+30) mg in a classical 3+3 dose escalation study. Briefly, 3 patients will be enrolled at dose level. Dose escalation to the next dose level will continue as long no DLT is observed in 3 patients (the incidence of DLT is ≤ 1/6) In any cohort, if 1/3 patients develop DLT, then 3 more patients will be added at that dose. The dose level at which more than 1/6 patients develop DLT will be considered the MTD and no further escalation will be done beyond the MTD. One dose level below the MTD will be considered for future trials. If MTD is not achieved, the highest dose (30+30) will be considered for future trials. If toxicity is seen at 30 mg, then de-escalation to 25 mg may be considered.To determine the maximum tolerated dose (MTD). First 3 patients will receive the study preparation once a day at 9 am (+/- 60 min) (i.e 5 mg of CBD and 5 mg of THC in a 400 mg capsule). Subsequent cohorts will be administered doses of 10 (10 mg of THC and CBD each), 20 (20+20) and 30 (30+30) mg in a classical 3+3 dose escalation study. Briefly, 3 patients will be enrolled at dose level. Dose escalation to the next dose level will continue as long no DLT is observed in 3 patients (the incidence of DLT is ≤ 1/6) In any cohort, if 1/3 patients develop DLT, then 3 more patients will be added at that dose. The dose level at which more than 1/6 patients develop DLT will be considered the MTD and no further escalation will be done beyond the MTD. One dose level below the MTD will be considered for future trials. If MTD is not achieved, the highest dose (30+30) will be considered for future trials. If toxicity is seen at 30 mg, then de-escalation to 25 mg may be considered.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Phase I Study of Safety and Feasibility of Ayurvedic Oral Cannabis Preparation in the Peri-operative Period in Breast and Oral Cavity Squamous Cell Cancer
Actual Study Start Date :
Jun 8, 2022
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cannabis

Cannabis capsules containing 5 mg of THC and CBD each or 2.5 mg of THC and CBD each.

Drug: Cannabis capsules
Cannabis capsules containing 5 mg of THC and CBD each or 2.5 mg of THC and CBD each.

Outcome Measures

Primary Outcome Measures

  1. To establish safe dose of oral cannabis preparation [From day 1 of IP dosing till 28 days .]

    Number of participants with treatment-related adverse events with respect to cardiovascular, central nervous system and psychotropic of cannabis as assessed by CTCAE v4.0

Secondary Outcome Measures

  1. Pharmacokinetic profiling [1.Pre operative day 1 to 5 - one each day before cannabinoid dosing, after dosing 30 minutes, 1 hour, 2 hour and 8 hour. 2. On day of surgery - Before and after the surgery 3. Post operative day 1 , day 2, day 3 and day 14]

    Blood samples collected during the administration of the IP for 5 days and up to 72 hours after surgery.

  2. Biomarker analysis- Transcitpomics [A baseline pre-cannabis tumor tissue sample will be collected before starting IP(day 0). Further blood and tumor as well as adjacent normal tissue samples will be collected during surgery (day6).]

    Tumor and normal tissue samples.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Histopathologically proven patients of breast or oral cavity SCC

  2. Age > 18 and < 65

  3. Operable cancers planned to undergo upfront curative surgery

  4. Patient fit for surgery (ASA Grade I / II)

  5. Patient Voluntarily willing to give consent for study

Exclusion Criteria:

  1. Planned for any other pre or peri-operative intervention such as neoadjuvant chemotherapy or targeted therapy or radiation

  2. Presence of medical disease such as pulmonary, renal, liver, gastro-intestinal disease which may interfere with any study specific procedure (deranged renal parameters > 1.5 times normal range or deranged liver function tests such as > 2.5 times raised liver enzymes)

  3. History of substance abuse (including cannabis-related products) or alcohol abuse

  4. Personal history of psychiatric disease or Significant family history of psychiatric disease

  5. Pregnancy and/or lactation

  6. Patients currently (within last 14 days before consenting) on other CNS depressants such as alcohol, barbiturates, benozodiazapines (like diazepam, alprazolam etc)

  7. Patients on other medications which will likely have a drug interaction with cannabis- such as clozapine, duloxetine, naproxen, cyclobenzaprine, olanzapine, haloperidol, and chlorpromazine, macrolides, calcium channel blockers, benzodiazepines, cyclosporine, sildenafil (and other PDE5 inhibitors), antihistamines, haloperidol, antiretrovirals

  8. Any other illness or abnormal laboratory investigations which the investigator considers as making the patients ineligible for the study

  9. Any patient with positive HIV, HBsAg, HCV status

Contacts and Locations

Locations

Site City State Country Postal Code
1 Tata Memorial Center Mumbai Maharashtra India 400012
2 Tata Memorial Hospital Mumbai Maharastra India 400012

Sponsors and Collaborators

  • Tata Memorial Hospital

Investigators

  • Principal Investigator: Rajendra A Badwe, MS, Director, Tata Memorial Centre

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Dr Rajendra A. Badwe, Doctor, Tata Memorial Hospital
ClinicalTrials.gov Identifier:
NCT05969314
Other Study ID Numbers:
  • TMH Project No. 3386
  • CTRI/2020/06/020649
First Posted:
Aug 1, 2023
Last Update Posted:
Aug 1, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Mouth Neoplasms

Study Results

No Results Posted as of Aug 1, 2023